Invesco
GLUE icon

Invesco’s Monte Rosa Therapeutics GLUE Stock Holding History

Invesco’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.35M Sell
97,013
-5,184
-5% -$98K ﹤0.01% 2513
2026
Q1 		$1.68M Sell
102,197
-260,016
-72% -$4.97M ﹤0.01% 2619
2025
Q4 		$5.68M Buy
362,213
+264,315
+270% +$3.56M ﹤0.01% 2188
2025
Q3 		$725K Buy
97,898
+32,509
+50% +$172K ﹤0.01% 3077
2025
Q2 		$295K Buy
65,389
+30,043
+85% +$134K ﹤0.01% 3367
2025
Q1 		$164K Buy
35,346
+22,499
+175% +$138K ﹤0.01% 3554
2024
Q4 		$89.2K Buy
+12,847
New +$96.4K ﹤0.01% 3641
2024
Q1 		– Sell
-10,518
Closed -$59.4K – 3894
2023
Q4 		$59.4K Buy
+10,518
New +$41.3K ﹤0.01% 3740
2022
Q4 		– Sell
-10,003
Closed -$81K – 4038
2022
Q3 		$81K Buy
+10,003
New +$91.9K ﹤0.01% 3867

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco's GLUE Position: Q2 2026 in Review

Invesco reduced its Monte Rosa Therapeutics (GLUE) stake by 5.1% in Q2 2026, selling an estimated $98K and leaving 97,013 shares worth $2.35M. The position accounts for ﹤0.01% of the portfolio, ranked #2513.

Invesco first reported a position in GLUE in Q3 2022 and has held it in 9 quarters since. The position peaked at $5.68M in Q4 2025. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Invesco held 97,013 shares of Monte Rosa Therapeutics worth $2.35M as of Q2 2026.
  • Invesco sold 5,184 Monte Rosa Therapeutics shares in Q2 2026, an estimated $98K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2513 holding.
  • Invesco first reported a position in Monte Rosa Therapeutics in Q3 2022 and has held it in 9 quarters since.
  • Invesco's Monte Rosa Therapeutics position peaked at $5.68M in Q4 2025.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.